1. A randomized trial assessing the utility of a test-dose program with taxanes
- Author
-
Jonathan E. Dowell, W. C. Hunt, Ian Rabinowitz, S. R. Shah, Jim A Krieger, B. L. Stanford, E. E. Ballard, and C. A. Jumper
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Test dose ,Cost Control ,Paclitaxel ,Docetaxel ,law.invention ,Drug Hypersensitivity ,chemistry.chemical_compound ,Randomized controlled trial ,law ,Internal medicine ,Neoplasms ,medicine ,Humans ,Aged ,Aged, 80 and over ,Taxane ,business.industry ,Incidence (epidemiology) ,Significant difference ,General Medicine ,Middle Aged ,Antineoplastic Agents, Phytogenic ,Surgery ,Hypersensitivity reaction ,chemistry ,Female ,Taxoids ,business ,medicine.drug - Abstract
Taxanes are commonly used anticancer agents with a potential of producing an allergic or hypersensitivity reaction (HSR). We performed a randomized study to evaluate the value of a test dose given prior to the full dose of either paclitaxel or docetaxel.Patients were randomly assigned to either the administration of the full dose or to the prior administration of a 1 mg intravenous test dose of either paclitaxel or docetaxel. The primary endpoints were severity of the HSR and the cost of drug wastage due to a HSR.Two hundred and eighteen patients were randomized from three different treatment sites. The overall incidence of HSR was 6.5% and there was no significant difference in the incidence of HSR in either group. The mean HSR severity grade was 2.8 for patients without a test dose and 2.3 for those receiving a test dose. There was, however, a reduction in the wastage of taxane in the test dose arm. Wastage avoided in the test dose arm was $1573 per patient who had a HSR and $104 per patient treated with a taxane.Although a test dose may not reduce the severity of a HSR with the administration of a taxane, it does reduce the cost associated with drug wastage.
- Published
- 2005